Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin by Mankhatitham, W et al.
POSTER PRESENTATION Open Access
Hepatotoxicity in patients co-infected with HIV
and tuberculosis while receiving NNRTI-based
antiretroviral regimen and rifampicin
W Mankhatitham, A Lueangniyomkul, W Manosuthi
*
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Objective
To evaluate the rate of and risk factors associated with
hepatotoxicity in tuberculosis (TB) and human immuno-
deficiency virus type 1 (HIV-1) co-infected patients
while receiving nonnucleoside reverse transcriptase inhi-
bitors (NNRTI)-based antiretroviral therapy (ART) and
rifampicin (RMP)-containing anti-TB regimens.
Methods
We analyzed data from an open label, randomized, com-
parative trial comparing treatment outcome between 71
TB/HIV-1 co-infected patients receiving efavirenz
(EFV)-based and nevirapine (NVP)-based ART and all
were receiving RMP containing anti-TB regimens.
Demographic data, liver function profile, CD4 cell
count, plasma HIV-1 RNA, hepatitis B surface antigen
a n da n t i -h e p a t i t i sCv i r u sa n t i b o d yw e r ec o l l e c t e d
before initiating ART (week 0). Liver enzymes and total
bilirubin level were monitored at 6 weeks, 12 weeks and
24 weeks after ART initiation. All patients were followed
until TB therapy was completed or 24 weeks after ART
initiation if TB therapy was not completed.
Results
Of 134 patients, mean (SD) age was 36.8 ± 8.6 years and
67.2% were male. HCV co-infection was found in 23.9%
of patients. Severe hepatotoxicity (grade 3 or 4) devel-
oped in 4 (23.9%) patients; 3 patients in NVP group and
1 patient in EFV group (P=0.355). Severe hyperbilirubi-
nemia (grade 3 or 4) occurred in 5 (7.7%) patients in
NVP group and 2 (2.9%) patients in EFV group
(P=0.264). By univariate analysis, cotrimoxazole use
(OR, 2.65; 95%CI, 0.99-7.02) and HCV co-infection (OR,
3.40; 95%CI, 1.49-7.37) were associated with grade 1-4
hepatotoxicity. By multivariate analysis, HCV co-infec-
tion (AOR, 3.03; 95%CI, 1.26-7.29) was the only inde-
pendent risk factor associated with grade 1-4
hepatotoxicity.
Conclusion
Monitoring of hepatotoxicity should be considered in
TB/HIV-1 co-infected patients who infected with HCV
and receiving NVP.
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